



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

16 July 2025
EMA/CVMP/231325/2025
Committee for Veterinary Medicinal Products (CVMP)

CVMP List of questions to be addressed by stakeholders

For quarter-based selective dry cow therapy

Article 141(1)(i) of Regulation (EU) 2019/6

Procedure number: EMA/REF/0000285673



On 9 July 2025, the German National Competent Authority presented to the European Medicines Agency a request for a scientific advice under Article 141(1)(i) of Regulation (EU) 2019/6 concerning quarter-based selective dry cow therapy and aimed at updating the product information of intramammary veterinary medicines used in cattle to allow for selective administration at quarter level, without contradicting national policies. Individually treating only sub clinically infected mastitis quarters with antibiotics at drying-off might result in a significant reduction in overall antibiotic use. The potential for this approach was already shown in various studies. More information on this procedure, including the letter of the German Competent Authority triggering the procedure, is available on the webpage of the procedure.

The Committee for Veterinary Medicinal Products (CVMP) commenced the consideration of the matter at its plenary meeting of July 2025 and will review all available data to provide a scientific advice.

Interested parties (e.g. marketing authorisation holders, academia, veterinary healthcare professionals, farmers) are invited to submit any information which may be relevant for this scientific advice by 9 October 2025.